Have a feature idea you'd love to see implemented?
Let us know!
IKT Inhibikase Therapeutics Inc
Price (delayed)
$2.52
Market cap
$18.81M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.89
Enterprise value
$16.08M
Inhibikase is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders that arise inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional
Highlights
The EPS has grown by 28% YoY and by 9% from the previous quarter
Inhibikase Therapeutics's net income has increased by 4.3% from the previous quarter and by 3.4% YoY
The company's debt fell by 28% QoQ but it rose by 19% YoY
The equity has dropped by 74% year-on-year and by 25% since the previous quarter
IKT's quick ratio has dropped by 72% year-on-year and by 7% since the previous quarter
Key stats
What are the main financial stats of IKT
Market
Valuations
Earnings
Shares outstanding
7.46M
Market cap
$18.81M
Enterprise value
$16.08M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.2
Price to sales (P/S)
238.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
202.06
Revenue
$79,570
EBIT
-$18.38M
EBITDA
-$18.36M
Free cash flow
-$16.47M
Per share
Balance sheet
Liquidity
EPS
-$2.89
Free cash flow per share
-$2.19
Book value per share
$0.79
Revenue per share
$0.01
TBVPS
$1.17
Total assets
$8.83M
Total liabilities
$3.73M
Debt
$355,086
Equity
$5.1M
Working capital
$4.9M
Debt to equity
0.07
Current ratio
2.32
Quick ratio
2.14
Net debt/EBITDA
0.15
Margins
Efficiency
Dividend
EBITDA margin
-23,069.1%
Gross margin
100%
Net margin
-23,102.2%
Operating margin
-23,885.1%
Return on assets
-140.6%
Return on equity
-194.2%
Return on invested capital
-704.6%
Return on capital employed
-358.9%
Return on sales
-23,102.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IKT stock price
How has the Inhibikase Therapeutics stock price performed over time
Intraday
3.7%
1 week
7.23%
1 month
119.13%
1 year
193.02%
YTD
98.43%
QTD
93.85%
Financial performance
How have Inhibikase Therapeutics's revenue and profit performed over time
Revenue
$79,570
Gross profit
$79,570
Operating income
-$19.01M
Net income
-$18.38M
Gross margin
100%
Net margin
-23,102.2%
The company's net margin has shrunk by 136% QoQ
IKT's operating margin has dropped by 132% since the previous quarter
The revenue has plunged by 68% YoY and by 59% from the previous quarter
Inhibikase Therapeutics's gross profit has plunged by 68% YoY and by 59% from the previous quarter
Growth
What is Inhibikase Therapeutics's growth rate over time
Valuation
What is Inhibikase Therapeutics stock price valuation
P/E
N/A
P/B
3.2
P/S
238.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
202.06
The EPS has grown by 28% YoY and by 9% from the previous quarter
The stock's price to book (P/B) is 167% more than its last 4 quarters average of 1.2
The equity has dropped by 74% year-on-year and by 25% since the previous quarter
The revenue has plunged by 68% YoY and by 59% from the previous quarter
Efficiency
How efficient is Inhibikase Therapeutics business performance
IKT's return on invested capital has dropped by 139% since the previous quarter
The ROS has plunged by 136% from the previous quarter
IKT's return on equity has dropped by 132% year-on-year and by 32% since the previous quarter
The return on assets has dropped by 92% year-on-year and by 20% since the previous quarter
Dividends
What is IKT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IKT.
Financial health
How did Inhibikase Therapeutics financials performed over time
The total assets is 137% greater than the total liabilities
IKT's quick ratio has dropped by 72% year-on-year and by 7% since the previous quarter
Inhibikase Therapeutics's current ratio has shrunk by 71% YoY and by 9% QoQ
The company's debt is 93% lower than its equity
The equity has dropped by 74% year-on-year and by 25% since the previous quarter
The company's debt fell by 28% QoQ but it rose by 19% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.